Mathieu Uzzan

Physician-scientist #IBD #immunology #MondorMICI

[UEGJ @UEGJournal]

🧩💊Anti-TNF therapy can induce #sarcoidosis-like lesions in #IBD

GETAID series (59 centres, n=14):
🔸71% dyspnea | 50% cough/fever
🔸86% mediastinal adenopathy
🔸Steroids → remission (median 84 days)
🔸No recurrences at 40 mo

📖 #OpenAccess 👉 https://t.co/ZHm162R83X

[Joseph Sleiman, MD, FACP @JosephHabibi_MD]

#CGH4ALL @AGA_CGH
Breast cancer is the most common malignancy🚨 in IBD.
This study evaluated the risk factors for incident cancer in IBD w/ hx of breast Ca.

🔗https://t.co/qcrBVX6BXv

Summary by @NAggarwalMD

@J_Kirchgesner @Pseksik @AlexandreNuzzo @snancey1 @MatFume @mat_uzz @VaysseCharlotte @SunandaKaneMD @UmaMahadevanIBD @Dcharabaty @IBD_Afzali @MRegueiroMD @JHashashMD @FarrayeIBD @ibdgijami @ibddocmaria @JPAchkarMD
@DrJordanAxelrad

[Esteban FV @Efuentesval]

👩‍⚕️👨‍⚕️Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis
▪︎GETAID multi🏥 retrospective study
▪︎N=169 pts
▪︎SFCR at weeks 8-14: upadacitinib (55.2%) 🆚️filgotinib (33.3%)🆚️tofacitinib (50%)
▪︎upa was associated with ⬆️ odds of SFCR compared to Filgo

[Harry Sokol @h_sokol]

Join us !
Open #Postdoc position in my lab (Paris, France), to work on the Role of the Gut #microbiota in Host Cells Energy Metabolism in Health and #IBD
see details here
🔽🔽🔽🔽
https://t.co/nUv6slIV6k

please RT

[Remo Panaccione, MD, FRCPC @RPanaccione]

What an absolute honour and privilege to host Prof. Harry Sokol @h_sokol at the University of Calgary as part of the @SnyderInstitute endowed chair series . A packed auditorium listening to a masterful talk on the gut microbiota and IBD. Harry is trailblazing the field .

[Julien Kirchgesner @J_Kirchgesner]

🌟 The #ECCO topical review on IBD Predictive Models has been published in @JCC_IBD!
🔍 In this review, we
1️⃣ Summarized all current models
2️⃣ Identified relevant methodology
3️⃣ Provided guidance for future models
🙏 Huge thanks to the team!
https://t.co/pU2B5IwNaW

[Gustave Roussy @GustaveRoussy]

Elles sont médecins, chercheuses et scientifiques à @GustaveRoussy.

💬 « J'ai été baignée dans cet univers féminin, avec ces femmes très fortes et très brillantes. »

À l'occasion de la Journée internationale des femmes et des filles de science, découvrez le portrait de la Dr @CBigenwald ⤵

[Mathieu Uzzan @mat_uzz]

Congrats SURVI guys

[SURVI @inteststroke]

1st patient included in the 1st randomized controlled trial in acute mesenteric ischemia! “ORal antibiotics In Acute Mesenteric Ischemia: a multicenter randomized controlled trial” #ORIAMI @AlexandreNuzzo @APHP #FHUTSUNAMI @oliviercorcos #SURVI @UP_Medecine

[Mathieu Uzzan @mat_uzz]

@EPierreMarie bonjour
Pourquoi indiquez-vous des h de fermeture pour la coulée verte alors que les agents municipaux ferment systématiquement 25-30 min avant l’heure annoncée et même une fois engagés nous font faire demi-tour avec poussettes et enfants ?
Merci pour votre réponse

[Xavier Lab @TheXavierLab]

1/3 Thrilled to share exciting new work in @Nature by @TouficMayassi, @li_chenhao, Åsa Segerstolpe, et al. Spatial profiling of mouse intestine reveals a landscape robust to perturbations in homeostatic drivers & adaptable in a spatially-restricted manner https://t.co/W9xvQJxVua

[GiulianaMagri @GMagri_Immuno]

📢Thrilled to share our work on the ontogeny, reactivity, and function of #IgA subclasses in homeostasis and #IBD! Huge thanks to Andrea, all our amazing collaborators, and @JExpMed for their support throughout the extended revision process! It's time to celebrate🥳!

[Mathieu Uzzan @mat_uzz]

@RestelliniS @HopitaldeLaTour @DavidLahari @J_Kirchgesner @MatFume @PGetaid Bienvenue 🇫🇷 🇧🇪 🇨🇭🤝

[Mathieu Uzzan @mat_uzz]

Happy to participate to this important and great team effort with incredible European colleagues and patients representatives @Y_ECCO_IBD !

[Pär Myrelid @PMyrelid]

Kicking off the work with the new #ECCO #ulcerativecolitis guidelines.

[Bram Verstockt @bverstockt]

Very happy this publication officially kicks off the @CollibriIbd consortium. Let’s continu collaborative research to move the needle for the benefit of our patients !

[GiulianaMagri @GMagri_Immuno]

Please RT 🙏!📢My lab at @UniBarcelona is seeking a highly motivated postdoc to lead an exciting new public-private collaborative project (UB, CRG, CSIC, OrikineBio) aimed at testing a potentially game-changing therapy for IBD. If interested, please contact me at [email protected].

[Mathieu Uzzan @mat_uzz]

@ZeClint Avec la majorité du revenu assuré par la secu (donc payé par l’état également) et en poussant à la consommation (scanner TAP fait en 2 fois etc)

[Mathieu Uzzan @mat_uzz]

@ZeClint Donc c est justifié qu en liberal on gagne 4 fois plus qu a l hôpital selon vous? Tout en n’assurant pas la continuité des soins (soirs et week end) ni les soins de recours.

[Mathieu Uzzan @mat_uzz]

Congrats! Huge achievement 👏 👏

[Julien Kirchgesner @J_Kirchgesner]

Delighted to announce that I've been awarded an @ERC_Research Starting Grant of ~1.5M € for my project FORECAST. I will develop in the next 5y a new framework using multiple sources of #RWD to assess the benefit-risk balance of #IBD treatments. #ERCStG
https://t.co/L00ZWZ0TSN

[Nathan Grellier @nathangrellier5]

Early ileal resection in Crohn's disease is not associated with severe long-term outcomes: the ERIC study

CD patients from Saint-Antoine and Beaujon Hospital comparing Early vs Late resections

https://t.co/HMzNko2fhC
@APandT
@PSeksik @J_Kirchgesner @h_sokol